Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Obexelimab in Systemic Lupus Erythematosus: NCT06559163 Clinical Landscape Report 2026
16 October 2026
NCT06559163 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
NKX-019 in Idiopathic Membranous Glomerulonephritis: NCT06557265 Clinical Landscape Report 2026
16 October 2026
NCT06557265 clinical landscape for Idiopathic Membranous Glomerulonephritis: endpoints, sponsor, phase, geography, readouts, asset context and development wh…
9 min read
TRIMELVax(University of Chile) in Metastatic melanoma: NCT06556004 Clinical Landscape Report 2026
16 October 2026
NCT06556004 clinical landscape for Metastatic melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Carboplatin in Advanced Endometrial Carcinoma: NCT06561308 Clinical Landscape Report 2026
16 October 2026
NCT06561308 clinical landscape for Advanced Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Recombinant Human Endostatin (Simcere) in Bone Cancer: NCT06562673 Clinical Landscape Report 2026
16 October 2026
NCT06562673 clinical landscape for Bone Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Canlitinib in Ewing Sarcoma: NCT06564272 Clinical Landscape Report 2026
16 October 2026
NCT06564272 clinical landscape for Ewing Sarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Ipilimumab in Locally Advanced Melanoma: NCT06566391 Clinical Landscape Report 2026
16 October 2026
NCT06566391 clinical landscape for Locally Advanced Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cretostimogene Grenadenorepvec in Non-Muscle Invasive Bladder Neoplasms: NCT06567743 Clinical Landscape Report 2026
16 October 2026
NCT06567743 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
LN-145-S1 in Relapsed Solid Neoplasm: NCT06566092 Clinical Landscape Report 2026
16 October 2026
NCT06566092 clinical landscape for Relapsed Solid Neoplasm: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Zanzalintinib in Leiomyosarcoma: NCT06571734 Clinical Landscape Report 2026
16 October 2026
NCT06571734 clinical landscape for Leiomyosarcoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cemiplimab-RWLC in Muscle Invasive Bladder Carcinoma: NCT06571708 Clinical Landscape Report 2026
16 October 2026
NCT06571708 clinical landscape for Muscle Invasive Bladder Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
Belimumab in Connective Tissue Diseases: NCT06572384 Clinical Landscape Report 2026
16 October 2026
NCT06572384 clinical landscape for Connective Tissue Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.